1. Contemporary benefit-harm profile over two decades in primary prophylactic ICD-therapy
- Author
-
Thomas Kleemann, Margit Strauss, Nicolas Werner, Andràs Fendt, Kleopatra Kouraki, Eleni Lampropoulou, and Ralf Zahn
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Defibrillation ,medicine.medical_treatment ,Clinical Investigations ,ICD complications ,primary prophylactic ICD ,030204 cardiovascular system & hematology ,Risk Assessment ,Sudden cardiac death ,03 medical and health sciences ,0302 clinical medicine ,implantable cardioverter defibrillator (ICD) ,Risk Factors ,Internal medicine ,Germany ,medicine ,Humans ,In patient ,030212 general & internal medicine ,Prospective Studies ,Registries ,business.industry ,Incidence ,Arrhythmias, Cardiac ,General Medicine ,Middle Aged ,medicine.disease ,Implantable cardioverter-defibrillator ,Icd therapy ,ICD shock ,defibrillation ,Icd implantation ,Defibrillators, Implantable ,Primary Prevention ,Survival Rate ,Death, Sudden, Cardiac ,Treatment Outcome ,Shock (circulatory) ,Female ,Icd shocks ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
Background Implantable cardioverter defibrillator (ICD) was implemented into clinical routine more than 20 years ago. Since then, ICD therapy became standard therapy for primary and secondary prevention of sudden cardiac death in clinical practice. Objectives Aim of the study was to evaluate the benefit‐harm profile of contemporary primary prophylactic ICD therapy. Methods A total of 1222 consecutive patients of a prospective single‐center ICD‐registry were analyzed who underwent primary prophylactic ICD implantation between 2000 and 2017. Patients were divided into two groups according to the implantation year: 2010‐2017 (group 1, n = 579) and 2000‐2009 (group 2, n = 643). Results The rate of estimated appropriate ICD therapy after 8 years was 51% in the 2000s and 42% in the 2010s (P
- Published
- 2019